Picture Berlin Partner Bionnale 2021 Digital Event 650x80px

Product › Details

BI 1467335 (PXS-4728A) (Boehringer / Pharmaxis)

	Next higher product group	semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1) inhibitor
	Status	2018-08-06 development p2 existent
	Organisation	Boehringer Ingelheim GmbH
	Group	Boehringer Ingelheim (Group)
	Organisation 2	Pharmaxis Ltd. (ASX: PXS)

Record changed: 2020-09-21

Picture [iito] Plain Stupid Simple 650x80px

More documents for anti-inflammatory drug

[1] Eleva GmbH. (1/6/21). "Press Release: Eleva Secures up to EUR 60 Million to Advance a Drug Candidate, Appoints New Board Member". Freiburg....
[2] Galapagos N.V.. (12/15/20). "Press Release: Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca (filgotinib)". Foster City, CA & Mechelen....
[3] Immune Regulation Ltd.. (9/21/20). "Press Release: Immune Regulation Limited Raises £40.6 Million / $53.4 Million Series B Equity Financing". London & Boston, MA....
[4] Boehringer Ingelheim. (9/7/20). "Press Release: Boehringer Ingelheim Discontinues Development of BI 1467335 for Diabetic Retinopathy". Ingelheim & Sydney....
[5] Galapagos N.V.. (8/19/20). "Press Release: Galapagos Announces that Gilead Received a Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis". Mechelen....
[6] Gesynta Pharma AB. (7/7/20). "Press Release: Gesynta Raises SEK 190 Million in Round Led by Hadean Ventures to Accelerate Development of First-in-class mPGES-1 Inhibitor GS-248 for Systemic Sclerosis". Stockholm....
[7] Galapagos N.V.. (4/16/20). "Press Release: Galapagos and Ryvu Announce Research Collaboration". Mechelen & Krakow....
[8] AM-Pharma B.V.. (3/31/20). "Press Release: AM-Pharma Increases Funding to €163m for Phase-III Trial of recAP in SA-AKI". Utrecht....
[9] Immune Regulation Ltd.. (3/27/20). "Press Release: Immune Regulation Ltd Appoints Jonathan Rigby as Chief Executive Officer"....
[10] Quench Bio. (1/27/20). "Press Release: Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases". Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

» top